Paul Resnick - MabVax Therapeutics Vice President and Chief Business Officer
President
Dr. Paul Resnick is Vice President and Chief Business Officer of the Company. He is an experienced biopharmaceutical executive with over 20 years of industry experience spanning large pharmaceutical and public and private biotechnology companies encompassing corporate development, product development, licensing and collaboration. FromJanuary 2013toMarch 2016, Dr. Resnick was Senior Vice President, for Juventas Therapeutics where he was responsible for business and commercial strategy and working with executive management overseeing clinical development and financial and business strategies. FromJanuary 2008toJanuary 2012he was Vice President, Business Development and member of the executive management team for Intellikine, Inc., responsible for managing alliances and leading the business development strategy that resulted in securing an acquisition by Takeda Pharmaceuticals. Earlier in his career Dr. Resnick held Director and Senior Director positions at Pfizer, Rinat Neuroscience, Intermune, Inc. and Roche Pharmaceuticals since 2016.
| Age | 59 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Phone | 858-259-9405 |
| Web | http://www.mabvax.com |
MabVax Therapeutics Management Efficiency
The company has return on total asset (ROA) of (61.26) % which means that it has lost $61.26 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (819.66) %, meaning that it created substantial loss on money invested by shareholders. MabVax Therapeutics' management efficiency ratios could be used to measure how well MabVax Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 2.69 M in liabilities. MabVax Therapeutics has a current ratio of 0.19, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist MabVax Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, MabVax Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like MabVax Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for MabVax to invest in growth at high rates of return. When we think about MabVax Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 13 records | PRESIDENT Age | ||
| O Kim | Franklin Wireless Corp | 52 | |
| Phillip Paccione | Skechers USA | 55 | |
| Michael Lesler | BCB Bancorp | 46 | |
| Carey Goldberg | JBG SMITH Properties | N/A | |
| Moina Banerjee | JBG SMITH Properties | 36 | |
| Ryan Bell | Encore Capital Group | 44 | |
| Michael Greenberg | Skechers USA | 61 | |
| Paul Grinberg | Encore Capital Group | 56 | |
| OC Kim | Franklin Wireless Corp | 60 | |
| David Paul | JBG SMITH Properties | 61 | |
| Philip Paccione | Skechers USA | 62 | |
| Jeffrey Greenberg | Skechers USA | 52 | |
| Mark Nason | Skechers USA | 62 | |
Management Performance
| Return On Equity | -819.66 | |||
| Return On Asset | -61.26 |
MabVax Therapeutics Leadership Team
Elected by the shareholders, the MabVax Therapeutics' board of directors comprises two types of representatives: MabVax Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MabVax. The board's role is to monitor MabVax Therapeutics' management team and ensure that shareholders' interests are well served. MabVax Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MabVax Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jenene Thomas, IR Contact Officer | ||
| Philip Livingston, Chief Science Officer, Director | ||
| Thomas Varvaro, Director | ||
| Jeffrey Ravetch, Director | ||
| Paul Resnick, Vice President and Chief Business Officer | ||
| Jeffrey Eisenberg, Director | ||
| Wolfgang Scholz, VP of Antibody Discovery | ||
| Gregory Hanson, CFO | ||
| David Hansen, Chairman of the Board and Presidentident, CEO | ||
| Paul Maffuid, VP of Pharmaceutical Devel. and Operations | ||
| Kenneth Cohen, Director | ||
| Paul Maier, Director | ||
| Robert Hoffman, Director |
MabVax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is MabVax Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -819.66 | |||
| Return On Asset | -61.26 | |||
| Profit Margin | (223.49) % | |||
| Operating Margin | (208.49) % | |||
| Current Valuation | 4.11 M | |||
| Shares Outstanding | 9.25 M | |||
| Shares Owned By Insiders | 9.09 % | |||
| Shares Owned By Institutions | 1.79 % | |||
| Number Of Shares Shorted | 296.46 K | |||
| Price To Earning | (0.16) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in MabVax Pink Sheet
If you are still planning to invest in MabVax Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MabVax Therapeutics' history and understand the potential risks before investing.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |